Johnson & Johnson reported a 9.1% increase in revenue to $24.6 billion for the fourth quarter of 2025, beating analysts' expectations[1]. The company's net income rose 49.1% to $5.1 billion and adjusted earnings per share reached $2.46, up 20.6% year over year[1]. The Innovative Medicine segment saw operational growth of 7.9%, with the largest contribution coming from oncology with growth of 24.8%[1]. For the full year 2025, the company will reach $94.2 billion in revenue, growing by 6.0% on a reported basis[1]. The company characterized 2025 as a "catapult year" when two new drugs, SHOCKWAVE and CARVYKTI, crossed the $1 billion mark in annual sales for the first time[1]. Johnson & Johnson now has 28 platforms with annual sales of at least $1 billion[1]. For 2026, the company expects sales in the range of 100 to 101 billion USD[3].